ProtecT试验:患者队列分析、基线风险分层与疾病进展
该研究分析ProtecT试验中局限性前列腺癌患者的基线临床病理特征与10年随访疾病进展的关系。结果显示34%患者为中高危,66%为低危;进展者中51%基线为ISUP分级组1,而无进展者中79%为分级组1(P<0.001)。进展者中低危比例低于稳定者(38% vs 69%,P<0.001)。
要点
- ProtecT队列中约三分之一(34%)为 intermediate/high-risk 前列腺癌, outcomes可推广至低危以外人群。
- 基线ISUP分级组、风险组、PSA、临床分期、阳性针数、肿瘤长度和神经侵犯与进展时间相关(P≤0.005)。
- 术后进展者更常见 higher Grade Group、病理分期、更大肿瘤、淋巴结侵犯和切缘阳性。
核心结论
- ProtecT队列中三分之一患者为中高危前列腺癌,10年随访结局数据可推广至低危以外人群。
研究设计与样本
- 对ProtecT试验中局限性前列腺癌患者进行队列分析,基线按临床分期、病理分级和PSA水平分层,使用Cox比例风险模型。
- 进展组198例,无进展组1409例,中位随访10年。
主要发现
- 34%(505例)为中高危,66%(973例)为低危。
- 进展组中51%(101例)基线为ISUP分级组1,30%(59例)为分级组2,19%(38例)为分级组3;无进展组分别为79%、17%、5%(P<0.001)。
- 进展组中38%为低危、62%为中高危;无进展组分别为69%和31%(P<0.001)。
- 治疗方式、年龄(65-69 vs 50-64岁)、PSA水平、分级组、临床分期、风险组、阳性针数、肿瘤长度和神经侵犯与进展时间相关(P≤0.005)。
- 术后进展者(19例)更可能有更高的分级组和病理分期、更大肿瘤、淋巴结侵犯和切缘阳性。
临床怎么用
- 基线风险分层应综合临床分期、ISUP分级组和PSA水平,以识别可能进展的中高危患者。
- 对于接受手术的患者,基线分级组高、肿瘤大、淋巴结侵犯和切缘阳性提示进展风险更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the hypothesis that the baseline clinico-pathological features of the men with localized prostate cancer (PCa) included in the ProtecT (Prostate Testing for Cancer and Treatment) trial who progressed (n = 198) at a 10-year median follow-up were different from those of men with stable disease (n = 1409). PATIENTS AND METHODS: We stratified the study participants at baseline according to risk of progression using clinical disease stage, pathological grade and PSA level, using Cox proportional hazard models. RESULTS: The findings showed that 34% of participants (n = 505) had intermediate- or high-risk PCa, and 66% (n = 973) had low-risk PCa. Of 198 participants who progressed, 101 (51%) had baseline International Society of Urological Pathology Grade Group 1, 59 (30%) Grade Group 2, and 38 (19%) Grade Group 3 PCa, compared with 79%, 17% and 5%, respectively, for 1409 participants without progression (P < 0.001). In participants with progression, 38% and 62% had baseline low- and intermediate-/high-risk disease, compared with 69% and 31% of participants with stable disease (P < 0.001). Treatment received, age (65-69 vs 50-64 years), PSA level, Grade Group, clinical stage, risk group, number of positive cores, tumour length and perineural invasion were associated with time to progression (P ≤ 0.005). Men progressing after surgery (n = 19) were more likely to have a higher Grade Group and pathological stage at surgery, larger tumours, lymph node involvement and positive margins. CONCLUSIONS: We demonstrate that one-third of the ProtecT cohort consists of people with intermediate-/high-risk disease, and the outcomes data at an average of 10 years' follow-up are generalizable beyond men with low-risk PCa.
引用
- Bryant RJ, Oxley J, Young GJ, et al. The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU Int. 2020. PMID: 31900963. doi:10.1111/bju.14987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。